Patents by Inventor Jingya Li

Jingya Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170313715
    Abstract: The present invention relates to six-membered ring benzo derivatives as a DPP-4 inhibitor and a use thereof. In particular, the present invention relates to a compound as shown in formula I, a pharmaceutical composition containing the compound as shown in formula I and a use of the compound in the preparation of drugs for treating DPP-4 related diseases or inhibiting DPP-4.
    Type: Application
    Filed: October 30, 2015
    Publication date: November 2, 2017
    Inventors: Honglin LI, Hualiang JIANG, Yufang XU, Jia LI, Zhenjiang ZHAO, Jingya LI, Hongling XU, Shiliang LI
  • Publication number: 20170257199
    Abstract: There is provided mechanisms for transmitting payload in a subframe. A method is performed by a first network device. The method comprises obtaining a transport block size (TBS) value by accessing an array storing a plurality of TBS values. The TBS value is proportional to number of user data symbols in a subframe of a given subframe length. One and the same array is accessed regardless of the given subframe length. The method comprises transmitting a physical channel carrying payload in the subframe to a second network device. The amount of data in the payload is determined by the TBS value.
    Type: Application
    Filed: November 4, 2015
    Publication date: September 7, 2017
    Inventors: Henrik Sahlin, Jingya Li, Niklas Andgart
  • Publication number: 20170247371
    Abstract: Provided are a class of pyrazolone compounds and a use thereof. In particular, a compound represented by formula I is provided, wherein the definition of each variable group is as described in the description. The compounds of formula (I) have a direct AMPK-activating activity and can significantly promote the phosphorylation of AMPK and ACC of L6 myocytes and HepG2 cells in a dose-dependent manner.
    Type: Application
    Filed: July 14, 2015
    Publication date: August 31, 2017
    Inventors: Fajun NAN, Jia LI, Jingya LI, Mei ZHANG, Dakai CHEN, Lina ZHANG, Runtao ZHANG, Zhifu XIE
  • Publication number: 20160316444
    Abstract: According to some embodiments, a method of synchronizing a wireless device with a network node comprises receiving a radio subframe transmitted from the network node. The MBSFN radio subframe comprises a first Primary Synchronization Signal (PSS) associated with a first Orthogonal Frequency Division Multiplexing (OFDM) symbol and paired with a first Secondary Synchronization Signal (SSS) associated with a second OFDM symbol. The method further comprises detecting the first PSS and detecting the first SSS within the radio subframe. The method determines system information associated with the network node based on the detected PSS and SSS. The radio subframe is transmitted from the network node as a Multimedia Broadcast Multicast Services Single-Frequency Network (MBSFN) subframe.
    Type: Application
    Filed: April 27, 2015
    Publication date: October 27, 2016
    Inventors: Emil Ringh, Mona Hashemi, Jingya Li, Henrik Sahlin
  • Publication number: 20160142989
    Abstract: According to some embodiments, a method of synchronizing a wireless device with a network node comprises receiving a radio subframe transmitted from the network node. The radio subframe comprises a first Primary Synchronization Signal (PSS) associated with a first Orthogonal Frequency Division Multiplexing (OFDM) symbol and a first plurality of subcarriers. The first PSS is paired with a first Secondary Synchronization Signal (SSS) associated with a second OFDM symbol and the first plurality of subcarriers. The radio subframe also comprises a second PSS associated with the first OFDM symbol and a second plurality of subcarriers. The second PSS is paired with a second SSS associated with the second OFDM symbol and the second plurality of subcarriers. The method further comprises inspecting the first plurality of subcarriers to detect the first PSS and the first SSS and inspecting the second plurality of subcarriers to detect the second PSS and the second SSS.
    Type: Application
    Filed: May 21, 2015
    Publication date: May 19, 2016
    Inventors: Mona Hashemi, Jingya Li, Emil Ringh, Henrik Sahlin
  • Publication number: 20160142241
    Abstract: According to some embodiments, a method of synchronizing a wireless device with a network node comprises receiving a radio subframe transmitted from the network node. The radio subframe comprises a first Primary Synchronization Signal (PSS) associated with a first Orthogonal Frequency Division Multiplexing (OFDM) symbol and paired with a first Secondary Synchronization Signal (SSS) associated with a second OFDM symbol. The radio subframe also comprises a second PSS associated with a third OFDM symbol and paired with a second SSS associated with a fourth OFDM symbol. The method further comprises detecting at least one of the first PSS and the second PSS within the radio subframe and detecting at least one of the first SSS and the second SSS within the radio subframe. The method determines system information associated with the network node based on the detected at least one PSS and the detected at least one SSS.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 19, 2016
    Inventors: Henrik SAHLIN, Mona HASHEMI, Jingya LI, Emil RINGH
  • Patent number: 9045491
    Abstract: Disclosed are new thienyl [3,2-d] pyrimidin-4-one compounds shown as the general formula (I), preparation method, pharmaceutical compositions and pharmacological use thereof. The compounds are strong DPPIV (dipeptide peptidase IV) inhibitors and can treat type II diabetes through well inhibiting DPPIV indirectly increasing the content of GLP-1 in vivo and inducing a series of physiological actions in vivo. Therefore, the compounds could be developed as new promising drugs for treating diabetes.
    Type: Grant
    Filed: October 23, 2012
    Date of Patent: June 2, 2015
    Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Cisen Pharmaceutical Co., Ltd.
    Inventors: Hong Liu, Jia Li, Jian Li, Jingya Li, Jiang Wang, Mingbo Su, Jie Lian, Hualiang Jiang, Kaixian Chen
  • Patent number: 8916572
    Abstract: Novel bis-quinazoline derivatives as tyrosine kinase inhibitors, synthesis of these compounds, and novel methods for treating tyrosine kinase mediated diseases or disorders using these compounds are disclosed. In particular, the present invention provides tethered quinazoline derivative dimers as inhibitors to the epidermal growth factor receptor (EGFR) tyrosine kinase, pharmaceutical compositions thereof, and their therapeutic uses for treating EGFR kinase-mediated diseases or disorders, such as various cancers, as well as synthetic methods for preparing these novel compounds.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: December 23, 2014
    Assignee: Tetranov International Inc.
    Inventors: Yusheng Wu, Chengshan Niu, Dapeng Zou, Jingya Li, Ruiyun Guo
  • Publication number: 20140323466
    Abstract: Disclosed are new thienyl[3,2-d]pyrimidin-4-one compounds shown as the general formula (I), preparation method, pharmaceutical compositions and pharmacological use thereof. The compounds are strong DPPIV (dipeptide peptidase IV) inhibitors and can treat type II diabetes through well inhibiting DPPIV indirectly increasing the content of GLP-1 in vivo and inducing a series of physiological actions in vivo. Therefore, the compounds could be developed as new promising drugs for treating diabetes.
    Type: Application
    Filed: October 23, 2012
    Publication date: October 30, 2014
    Inventors: Hong Liu, Jia Li, Jian Li, Jingya Li, Jiang Wang, Mingbo Su, Jie Lian, Hualiang Jiang, Kaixian Chen
  • Publication number: 20130296348
    Abstract: Novel bis-quinazoline derivatives as tyrosine kinase inhibitors, synthesis of these compounds, and novel methods for treating tyrosine kinase mediated diseases or disorders using these compounds are disclosed. In particular, the present invention provides tethered quinazoline derivative dimers as inhibitors to the epidermal growth factor receptor (EGFR) tyrosine kinase, pharmaceutical compositions thereof, and their therapeutic uses for treating EGFR kinase-mediated diseases or disorders, such as various cancers, as well as synthetic methods for preparing these novel compounds.
    Type: Application
    Filed: May 6, 2013
    Publication date: November 7, 2013
    Applicant: Tetranov International, Inc
    Inventors: Yusheng Wu, Chengshan Niu, Dapeng Zou, Jingya Li, Ruiyun Guo
  • Patent number: 8183383
    Abstract: PTP1B inhibitors with the following structure (formula I). Experiments indicate that these inhibitors can effectively inhibit the activity of protein tyrosine phosphatase 1B (PTP1B). They can be used as insulin sensitisers. They can be used to prevent, delay or treat diseases which are related to insulin antagonism mediated by PTP1B, especially diabetes type II and obesity. The invention also provides methods for preparing these inhibitors.
    Type: Grant
    Filed: February 26, 2008
    Date of Patent: May 22, 2012
    Assignee: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Fajun Nan, Jia Li, Yi Wei, Wei Zhang, Jingya Li, Lei Shi
  • Publication number: 20100197927
    Abstract: PTP1B inhibitors with the following structure (formula I). Experiments indicate that these inhibitors can effectively inhibit the activity of protein tyrosine phosphatase 1B (PTP1B). They can be used as insulin sensitisers. They can be used to prevent, delay or treat diseases which are related to insulin antagonism mediated by PTP1B, especially diabetes type II and obesity. The invention also provides methods for preparing these inhibitors.
    Type: Application
    Filed: February 26, 2008
    Publication date: August 5, 2010
    Applicant: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Fajun Nan, Jia Li, Yi Wei, Wei Zhang, Jingya Li, Lei Shi
  • Publication number: 20100113494
    Abstract: The present invention provides 13,13a-dihydroberberine derivatives or their physiologically acceptable salts represented by the following formula, pharmaceutical compositions comprising the same, and uses thereof. The 13,13a-dihydroberberine derivatives have an activity of promoting glucose absorption in muscle cells, and the whole animal tests show that the present compounds have effects on improving glucose-tolerance and insulin-resistance, facilitating weight loss, relieving fatty liver and the like. Thus, the present compounds can be used in treating diabetes mellitus, adiposity, fatty liver and complications thereof induced by insulin resistance.
    Type: Application
    Filed: September 30, 2007
    Publication date: May 6, 2010
    Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Lihong Hu, Jia Li, Jingya Li, Hankun Zhang, Zhe Cheng, Jiming Ye, David E. James, Edward W. Kraegen
  • Publication number: 20050113420
    Abstract: The invention provides a new methionine aminopeptidase inhibitors with the following formula (I), wherein R1, R2, R3, R4, R5, R6 and X have the meanings given in the description. Pharmacological experiment shows that they display good inhibition activity for methionine aminopeptidase.
    Type: Application
    Filed: March 25, 2003
    Publication date: May 26, 2005
    Inventors: Fajun Nan, Qizhuang Ye, Jingya Li, Zhiying Liu, Qunli Luo, Yongmei Cui